Yanqiu Zhao

机构：Qingdao University of Science and Technology, Henan Cancer Hospital

发表论文 203 篇 · 总被引 7515 次 · h-index 33

代表论文

• Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China (2025 · The Lancet · 被引 154)
• Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer (2025 · New England Journal of Medicine · 被引 101)
• Efficacy and safety of MHB088C, a novel B7-H3-targeted ADC, in patients with relapsed extensive-stage small cell lung cancer (ES-SCLC): Subgroup analysis from a phase 1/2 multicenter study. (2025 · Journal of Clinical Oncology · 被引 6)
• First report of efficacy and safety results from a phase 2 trial evaluating BNT327/PM8002 plus chemotherapy (chemo) as first-line treatment (1L) in unresectable malignant mesothelioma. (2025 · Journal of Clinical Oncology · 被引 5)
• Promising early results of MHB088C (B7-H3 ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) from a phase 1/2 multicenter study. (2025 · Journal of Clinical Oncology · 被引 4)
• Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study (2025 · Pneumologie · 被引 4)